Again issues with 1067 trial design They did not give details about the trial design and it is not clear if they would give a head to head comparison with one of the marketed products.
So the final PR would be "1067 showed efficiency in clinical trial" How good is that? There is no comparision that one can judge.
I am telling you months in advance, this would be the next carrot to fool investors. And even with their "positive" data deal may not come.
There are always holes in every step.